Literature DB >> 31894103

Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET.

Renaud La Joie1, Adrienne V Visani2, Suzanne L Baker3, Jesse A Brown2, Viktoriya Bourakova2, Jungho Cha2, Kiran Chaudhary2, Lauren Edwards2, Leonardo Iaccarino2, Mustafa Janabi3, Orit H Lesman-Segev2, Zachary A Miller2, David C Perry2, James P O'Neil3, Julie Pham2, Julio C Rojas2, Howard J Rosen2, William W Seeley2, Richard M Tsai2, Bruce L Miller2, William J Jagust3,4, Gil D Rabinovici2,3,4,5.   

Abstract

β-Amyloid plaques and tau-containing neurofibrillary tangles are the two neuropathological hallmarks of Alzheimer's disease (AD) and are thought to play crucial roles in a neurodegenerative cascade leading to dementia. Both lesions can now be visualized in vivo using positron emission tomography (PET) radiotracers, opening new opportunities to study disease mechanisms and improve patients' diagnostic and prognostic evaluation. In a group of 32 patients at early symptomatic AD stages, we tested whether β-amyloid and tau-PET could predict subsequent brain atrophy measured using longitudinal magnetic resonance imaging acquired at the time of PET and 15 months later. Quantitative analyses showed that the global intensity of tau-PET, but not β-amyloid-PET, signal predicted the rate of subsequent atrophy, independent of baseline cortical thickness. Additional investigations demonstrated that the specific distribution of tau-PET signal was a strong indicator of the topography of future atrophy at the single patient level and that the relationship between baseline tau-PET and subsequent atrophy was particularly strong in younger patients. These data support disease models in which tau pathology is a major driver of local neurodegeneration and highlight the relevance of tau-PET as a precision medicine tool to help predict individual patient's progression and design future clinical trials.
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31894103      PMCID: PMC7035952          DOI: 10.1126/scitranslmed.aau5732

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  70 in total

1.  Normative morphometric data for cerebral cortical areas over the lifetime of the adult human brain.

Authors:  Olivier Potvin; Louis Dieumegarde; Simon Duchesne
Journal:  Neuroimage       Date:  2017-05-13       Impact factor: 6.556

2.  CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease.

Authors:  Anders M Fjell; Kristine B Walhovd; Christine Fennema-Notestine; Linda K McEvoy; Donald J Hagler; Dominic Holland; James B Brewer; Anders M Dale
Journal:  J Neurosci       Date:  2010-02-10       Impact factor: 6.167

3.  Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD.

Authors:  G D Rabinovici; H J Rosen; A Alkalay; J Kornak; A J Furst; N Agarwal; E C Mormino; J P O'Neil; M Janabi; A Karydas; M E Growdon; J Y Jang; E J Huang; S J Dearmond; J Q Trojanowski; L T Grinberg; M L Gorno-Tempini; W W Seeley; B L Miller; W J Jagust
Journal:  Neurology       Date:  2011-11-30       Impact factor: 9.910

4.  Distinct Interplay Between Atrophy and Hypometabolism in Alzheimer's Versus Semantic Dementia.

Authors:  Alexandre Bejanin; Renaud La Joie; Brigitte Landeau; Serge Belliard; Vincent de La Sayette; Francis Eustache; Béatrice Desgranges; Gaël Chételat
Journal:  Cereb Cortex       Date:  2019-05-01       Impact factor: 5.357

5.  Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia.

Authors:  P Bourgeat; G Chételat; V L Villemagne; J Fripp; P Raniga; K Pike; O Acosta; C Szoeke; S Ourselin; D Ames; K A Ellis; R N Martins; C L Masters; C C Rowe; O Salvado
Journal:  Neurology       Date:  2010-01-12       Impact factor: 9.910

6.  Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.

Authors:  Alexandre Bejanin; Daniel R Schonhaut; Renaud La Joie; Joel H Kramer; Suzanne L Baker; Natasha Sosa; Nagehan Ayakta; Averill Cantwell; Mustafa Janabi; Mariella Lauriola; James P O'Neil; Maria L Gorno-Tempini; Zachary A Miller; Howard J Rosen; Bruce L Miller; William J Jagust; Gil D Rabinovici
Journal:  Brain       Date:  2017-12-01       Impact factor: 13.501

7.  Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration.

Authors:  Kelvin K Leung; Jonathan W Bartlett; Josephine Barnes; Emily N Manning; Sebastien Ourselin; Nick C Fox
Journal:  Neurology       Date:  2013-01-09       Impact factor: 9.910

8.  Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case.

Authors:  Marta Marquié; Eline E Verwer; Avery C Meltzer; Sally Ji Who Kim; Cinthya Agüero; Jose Gonzalez; Sara J Makaretz; Michael Siao Tick Chong; Prianca Ramanan; Ana C Amaral; Marc D Normandin; Charles R Vanderburg; Stephen N Gomperts; Keith A Johnson; Matthew P Frosch; Teresa Gómez-Isla
Journal:  Acta Neuropathol Commun       Date:  2017-10-19       Impact factor: 7.801

9.  Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study.

Authors:  Keith A Josephs; Dennis W Dickson; Nirubol Tosakulwong; Stephen D Weigand; Melissa E Murray; Leonard Petrucelli; Amanda M Liesinger; Matthew L Senjem; Anthony J Spychalla; David S Knopman; Joseph E Parisi; Ronald C Petersen; Clifford R Jack; Jennifer L Whitwell
Journal:  Lancet Neurol       Date:  2017-09-11       Impact factor: 44.182

Review 10.  Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development.

Authors:  Gil D Rabinovici; Maria C Carrillo; Mark Forman; Susan DeSanti; David S Miller; Nicholas Kozauer; Ronald C Petersen; Christopher Randolph; David S Knopman; Eric E Smith; Maria Isaac; Niklas Mattsson; Lisa J Bain; James A Hendrix; John R Sims
Journal:  Alzheimers Dement (N Y)       Date:  2016-09-20
View more
  107 in total

Review 1.  Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies.

Authors:  Che-Wei Chang; Eric Shao; Lennart Mucke
Journal:  Science       Date:  2021-02-26       Impact factor: 47.728

Review 2.  Alzheimer's disease: phenotypic approaches using disease models and the targeting of tau protein.

Authors:  Elisabetta Lauretti; Domenico Praticò
Journal:  Expert Opin Ther Targets       Date:  2020-03-06       Impact factor: 6.902

3.  Inferior temporal tau is associated with accelerated prospective cortical thinning in clinically normal older adults.

Authors:  Matthew R Scott; Olivia L Hampton; Rachel F Buckley; Jasmeer P Chhatwal; Bernard J Hanseeuw; Heidi Il Jacobs; Michael J Properzi; Justin S Sanchez; Keith A Johnson; Reisa A Sperling; Aaron P Schultz
Journal:  Neuroimage       Date:  2020-06-05       Impact factor: 6.556

4.  Reduced synchrony in alpha oscillations during life predicts post mortem neurofibrillary tangle density in early-onset and atypical Alzheimer's disease.

Authors:  Kamalini G Ranasinghe; Cathrine Petersen; Kiwamu Kudo; Danielle Mizuiri; Katherine P Rankin; Gil D Rabinovici; Maria Luisa Gorno-Tempini; William W Seeley; Salvatore Spina; Bruce L Miller; Keith Vossel; Lea T Grinberg; Srikantan S Nagarajan
Journal:  Alzheimers Dement       Date:  2021-04-21       Impact factor: 21.566

5.  Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia.

Authors:  Chao Wang; Monica Xiong; Maud Gratuze; Xin Bao; Yang Shi; Prabhakar Sairam Andhey; Melissa Manis; Caitlin Schroeder; Zhuoran Yin; Charlotte Madore; Oleg Butovsky; Maxim Artyomov; Jason D Ulrich; David M Holtzman
Journal:  Neuron       Date:  2021-04-07       Impact factor: 17.173

Review 6.  Graph Models of Pathology Spread in Alzheimer's Disease: An Alternative to Conventional Graph Theoretic Analysis.

Authors:  Ashish Raj
Journal:  Brain Connect       Date:  2021-05-25

Review 7.  Alzheimer's disease.

Authors:  Philip Scheltens; Bart De Strooper; Miia Kivipelto; Henne Holstege; Gael Chételat; Charlotte E Teunissen; Jeffrey Cummings; Wiesje M van der Flier
Journal:  Lancet       Date:  2021-03-02       Impact factor: 79.321

8.  Association of Midlife Depressive Symptoms with Regional Amyloid-β and Tau in the Framingham Heart Study.

Authors:  Mitzi M Gonzales; Jasmeet Samra; Adrienne O'Donnell; R Scott Mackin; Joel Salinas; Mini E Jacob; Claudia L Satizabal; Hugo J Aparicio; Emma G Thibault; Justin S Sanchez; Rebecca Finney; Zoe B Rubinstein; Danielle V Mayblyum; Ron J Killiany; Charlie S Decarli; Keith A Johnson; Alexa S Beiser; Sudha Seshadri
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

9.  Spatial Relationships between Molecular Pathology and Neurodegeneration in the Alzheimer's Disease Continuum.

Authors:  Leonardo Iaccarino; Renaud La Joie; Lauren Edwards; Amelia Strom; Daniel R Schonhaut; Rik Ossenkoppele; Julie Pham; Taylor Mellinger; Mustafa Janabi; Suzanne L Baker; David Soleimani-Meigooni; Howard J Rosen; Bruce L Miller; William J Jagust; Gil D Rabinovici
Journal:  Cereb Cortex       Date:  2021-01-01       Impact factor: 5.357

10.  PAC1 receptor-mediated clearance of tau in postsynaptic compartments attenuates tau pathology in mouse brain.

Authors:  Ari W Schaler; Avery M Runyan; Catherine L Clelland; Eric J Sydney; Stephanie L Fowler; Helen Y Figueroa; Seiji Shioda; Ismael Santa-Maria; Karen E Duff; Natura Myeku
Journal:  Sci Transl Med       Date:  2021-05-26       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.